Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations
Authors:
- Linda Björkhem-BergmanLinda Björkhem-Bergman
- Eva Andersén-KarlssonEAEva Andersén-Karlsson
- Richard LaingRLRichard Laing
- Eduardo DiogeneEDEduardo Diogene
- Oyvind MelienOMOyvind Melien
- Malena JirlowMJMalena Jirlow
- Rickard E MalmströmRMRickard E Malmström
- Sabine VoglerSVSabine Vogler
- Brian GodmanBGBrian Godman
- Lars L GustafssonLGLars L Gustafsson
- 3 May 2013
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (S1) , 73-78
Abstract
Purpose In September 2012 an interactive course on the “Interface Management of Pharmacotherapy” was organized by the Stockholm Drug and Therapeutics Committee in cooperation with Department of Clinical Pharmacology at Karolinska Institutet and at Karolinska University Hospital in Stockholm, Sweden, in collaboration with the WHO. The basis for the course was the “Stockholm model” for the rational use of medicines but also contained presentations about successful models in interface management of pharmacotherapy in other European countries. Methods The “Stockholm model” consists of 8 components: 1) Independent Drug and Therapeutics Committee with key role for respected drug experts with policy for “interest of conflicts”, 2) The “Wise List”, recommendations of medicines jointly for primary and hospital care, 3) Communication strategy with continuous medical education, 4) Systematic introduction of new expensive medicines, 5) E-pharmacological support at “point of care”, 6) Methods and tools for follow-up of medicines use, 7) Medicines policy strategy and 8) Operative resources. Results The course highlighted the importance of efficient and targeted communication of drug recommendations building on trust among prescribers and patients for the guidelines to achieve high adherence. Trust is achieved by independent Drug and Therapeutics Committees with a key role for respected experts and a strict policy for “conflicts of interest”. Representations of GPs are also crucial for successful implementation, being the link between evidence based medicine and practice. Conclusion The successful models in Scotland and in Stockholm as well as the ongoing work in Catalonia were considered as examples of multifaceted approaches to improve the quality of medicine use across primary and hospital care.Keywords
This publication has 16 references indexed in Scilit:
- Improving the managed entry of new medicines: sharing experiences across EuropeExpert Review of Pharmacoeconomics & Outcomes Research, 2012
- A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market PricingApplied Health Economics and Health Policy, 2012
- The ‘Wise List’– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in StockholmBasic & Clinical Pharmacology & Toxicology, 2011
- What public policies have been more effective in promoting rational prescription of drugs?Journal of Epidemiology and Community Health, 2010
- Management of medication use in ScotlandAmerican Journal of Health-System Pharmacy, 2010
- Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future directionExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region—Bridging the gap between knowledge and practiceInternational Journal of Medical Informatics, 2007
- From best evidence to best practice: effective implementation of change in patients' careThe Lancet, 2003
- 25 years of the WHO essential medicines lists: progress and challengesThe Lancet, 2003
- The essential drugs programme in Zimbabwe: new approaches to trainingHealth Policy and Planning, 1989